United Therapeutics: In Progress -- New Organs For Old At Scale (NASDAQ:UTHR)

Core Insights - The article discusses United Therapeutics (UTHR) and its position in the pulmonary diseases market, indicating a growing company with a strong franchise [1]. Group 1 - The author has previously rated United Therapeutics as a hold, reflecting a cautious outlook on the stock's performance [1]. - The investment approach is described as a learning process, emphasizing that both successes and failures contribute to valuable lessons [1]. - The author has focused research on healthcare stocks for approximately five years, indicating a specialized knowledge in this sector [1].